DMTK · Dermtech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.85M | - | $3.92M | $3.98M | $3.48M | - | $3.57M | $4.23M | $3.72M | - |
| Cost of Revenue | $3.13M | - | $3.74M | $3.97M | $3.82M | - | $3.69M | $3.27M | $3.55M | - |
| Gross Profit | $713.0K | - | $172.0K | $8.0K | ($344.0K) | - | ($121.0K) | $960.0K | $164.0K | - |
| R&D | $3.27M | - | $3.60M | $3.89M | $4.41M | - | $5.70M | $6.92M | $6.34M | - |
| SG&A | $10.14M | - | $8.26M | $15.22M | $11.88M | - | $8.81M | $8.88M | $8.57M | - |
| Total Operating Expenses | $21.22M | - | $19.98M | $32.14M | $31.70M | - | $29.14M | $30.79M | $30.36M | - |
| D&A | $490.0K | - | - | - | $466.0K | - | $400.0K | $400.0K | $100.0K | - |
| Operating Income | ($20.51M) | - | ($19.81M) | ($32.13M) | ($32.05M) | - | ($29.26M) | ($29.83M) | ($30.19M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($20.01M) | - | ($19.16M) | ($31.36M) | ($31.27M) | - | ($28.77M) | ($29.58M) | ($30.11M) | - |
| EPS - Basic | ($0.58) | - | ($0.57) | ($0.99) | ($1.01) | - | ($0.96) | ($0.99) | - | - |
| EPS - Diluted | ($0.58) | - | ($0.57) | ($0.99) | ($1.02) | - | ($0.96) | ($0.59) | - | - |
Balance Sheet
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.58M | $36.74M | $37.23M | $42.79M | $48.44M | $77.76M | $95.49M | $120.33M | $145.05M | $176.88M |
| Accounts Receivable | $2.50M | $2.58M | $3.60M | $3.87M | $3.69M | $4.17M | $6.10M | $5.96M | $5.00M | $3.85M |
| Inventory | $831.0K | $1.00M | $1.20M | $1.35M | $1.57M | $1.76M | $1.39M | $1.43M | $763.0K | $480.0K |
| Accounts Payable | $1.91M | $1.48M | $1.70M | $2.32M | $1.68M | $2.42M | $3.00M | $861.0K | $1.57M | $2.88M |
| Current Assets | $44.20M | $61.75M | $75.93M | $93.74M | $112.39M | $136.04M | $160.83M | $183.87M | $208.12M | $232.82M |
| Total Assets | $102.97M | $121.93M | $137.90M | $157.07M | $177.12M | $202.07M | $194.06M | $216.11M | $239.52M | $248.31M |
| Current Liabilities | $12.52M | $13.45M | $12.64M | $16.01M | $16.14M | $15.64M | $16.99M | $15.09M | $14.42M | $12.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $62.98M | $64.75M | $64.83M | $69.00M | $69.88M | $69.72M | $39.08M | $37.53M | $36.04M | $18.61M |
| Stockholders' Equity | $39.99M | $57.17M | $73.06M | $88.08M | $107.24M | $132.35M | $154.99M | $178.58M | $203.48M | $229.70M |
| Retained Earnings | ($443.94M) | ($423.94M) | ($404.84M) | ($385.68M) | ($354.32M) | ($323.05M) | ($294.82M) | ($266.05M) | ($236.47M) | ($206.36M) |
Cash Flow
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($17.12M) | - | - | - | ($22.03M) | - | - | - | ($24.82M) | - |
| Investing Cash Flow | $7.83M | - | - | - | ($8.19M) | - | - | - | ($7.53M) | - |
| Financing Cash Flow | $122.0K | - | - | - | $916.0K | - | - | - | $527.0K | - |
| CapEx | $0 | - | - | - | $757.0K | - | - | - | $646.0K | - |
| Free Cash Flow | ($17.12M) | - | - | - | ($22.79M) | - | - | - | ($25.47M) | - |
Ratios
| Metric | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 18.5% | - | 4.4% | 0.2% | -9.9% | - | -3.4% | 22.7% | 4.4% | - |
| Operating margin | -533.4% | - | -506.0% | -807.3% | -921.6% | - | -818.9% | -704.8% | -812.0% | - |
| EBITDA margin | -520.6% | - | - | - | -908.2% | - | -807.8% | -695.3% | -809.3% | - |
| Net margin | -520.4% | - | -489.5% | -788.0% | -899.3% | - | -805.3% | -698.8% | -809.8% | - |
| Free cash flow margin | -445.2% | - | - | - | -655.3% | - | - | - | -685.0% | - |
| FCF / Net income | 0.86 | - | - | - | 0.73 | - | - | - | 0.85 | - |
| R&D / Revenue | 84.9% | - | 91.8% | 97.7% | 126.8% | - | 159.6% | 163.4% | 170.5% | - |
| SG&A / Revenue | 263.7% | - | 211.1% | 382.4% | 341.5% | - | 246.5% | 209.7% | 230.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.4% | - | -13.9% | -20.0% | -17.7% | - | -14.8% | -13.7% | -12.6% | - |
| Return on equity | -50.0% | - | -26.2% | -35.6% | -29.2% | - | -18.6% | -16.6% | -14.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.53 | 4.59 | 6.01 | 5.85 | 6.96 | 8.70 | 9.47 | 12.19 | 14.43 | 19.11 |
| Quick ratio | 3.46 | 4.52 | 5.91 | 5.77 | 6.87 | 8.59 | 9.39 | 12.09 | 14.38 | 19.07 |
| Cash ratio | 2.20 | 2.73 | 2.95 | 2.67 | 3.00 | 4.97 | 5.62 | 7.98 | 10.06 | 14.52 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.57 | 2.13 | 1.89 | 1.78 | 1.65 | 1.53 | 1.25 | 1.21 | 1.18 | 1.08 |
| Liabilities / Assets | 0.61 | 0.53 | 0.47 | 0.44 | 0.39 | 0.35 | 0.20 | 0.17 | 0.15 | 0.07 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.03 | 0.03 | 0.02 | - | 0.02 | 0.02 | 0.02 | - |
| Inventory turnover | 3.77 | - | 3.13 | 2.94 | 2.43 | - | 2.66 | 2.29 | 4.66 | - |
| Days sales outstanding | 237d | - | 336d | 354d | 387d | - | 623d | 514d | 490d | - |
| Days inventory outstanding | 97d | - | 117d | 124d | 150d | - | 137d | 160d | 78d | - |
| Days payable outstanding | 223d | - | 166d | 214d | 160d | - | 296d | 96d | 162d | - |
| Cash conversion cycle | 111d | - | 287d | 265d | 377d | - | 465d | 578d | 407d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.6% | - | 9.6% | -6.0% | -6.5% | - | 17.9% | 35.7% | 47.3% | - |
| Revenue CAGR (3y) | 15.1% | - | 42.2% | 86.5% | 30.7% | - | 77.3% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | -99.2% | - | - | - | 93.9% | -68.6% | - |
| Operating income growth (YoY) | 36.0% | - | 32.3% | -7.7% | -6.1% | - | -44.0% | -72.4% | -125.1% | - |
| Net income growth (YoY) | 36.0% | - | 33.4% | -6.0% | -3.9% | - | -43.1% | -73.0% | -99.8% | - |
| EPS growth (YoY) | 43.1% | - | 40.6% | -67.8% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 24.9% | - | - | - | 10.5% | - | - | - | -137.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.7% | -56.8% | -52.9% | -50.7% | -47.3% | -42.4% | -38.5% | -33.2% | -20.8% | 261.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$15.30M totalTest Revenue$14.38M · 94.0%
Contract Revenue Smart Stickers$592.0K · 3.9%
Contract Revenue RNAExtractions$230.0K · 1.5%
Contract Revenue Project Management Fees$90.0K · 0.6%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing DermTech against the 5 most active filers in the same SIC group.